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 We demonstrated the feasibility of conducting a longitudinal, household-based pilot study 
to assess meningococcal carriage using standard clinical and laboratory methods in a low-
resource setting in the African meningitis belt. 
 During the cross-sectional screening visit, 20 carriers were identified from 400 individuals 
from 116 households.  
 Over the 18 months of follow-up among 202 individuals from 20 households, 73 carriage 
events were identified from 1,422 swabs and 16.3% of individuals (33/202) were identified 
as carriers at least once.  
 The estimated average duration of meningococcal carriage of any serogroup was 2.9 months 
(95% CI: 1.6, 5.4). The individual acquisition rate per month was 2.3 per 100 (95% CI: 1.3, 
3.8). 
 Six serogroup W carrier isolates and 9 serogroup Y carrier isolates were identified from all 
swabs collected; the majority of isolates were non-groupable (84%). No serogroup A, C, or X 
carriers were identified. 
 Our results suggest that males and children may acquire and clear carriage more quickly 
than females and adults, respectively. These results apply to non-groupable meningococci, 
primarily, given that 84% of all isolates were non-groupable. 
 
 
ABSTRACT 
 
Objectives: Carriers of Neisseria meningitidis are a key source of transmission. In the African meningitis 
belt, where risk of meningococcal disease is highest, a greater understanding of meningococcal carriage 
dynamics is needed. 
 
Methods: We randomly selected an age-stratified sample of 400 residents from 116 households in 
Bamako, Mali, and collected pharyngeal swabs in May 2010. A month later, we enrolled all 202 residents 
of 20 of these households (6 with known carriers) and collected swabs monthly for 6 months prior to 
MenAfriVac vaccine introduction and returned 10 months later to collect swabs monthly for 3 months. 
We used standard bacteriological methods to identify N. meningitidis carriers and fit hidden Markov 
models to assess acquisition and clearance overall and by sex and age. 
 
Results: During the cross-sectional study 5.0% of individuals (20/400) were carriers. During the 
longitudinal study, 73 carriage events were identified from 1,422 swabs analyzed and 16.3% of 
individuals (33/202) were identified as carriers at least once. The vast majority of isolates were non-
groupable; no serogroup A carriers were identified.  
 
Conclusions: Our results suggest that the duration of carriage with any N. meningitidis averages 2.9 
months and that males and children acquire and lose carriage more frequently in an urban, low-
resource setting in Mali. Our study informed the design of a larger study across seven countries of the 
meningitis belt.  
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BACKGROUND  
The African meningitis belt is an area of increased risk of bacterial meningitis characterized by distinct 
seasonal patterns in disease incidence with peaks in the dry season, large-scale epidemics every 5-12 
years, and inter and intra-annual geographic variation (1-4). This region, which stretches from Ethiopia 
in the east to Senegal and The Gambia in the west, has suffered high morbidity and mortality due to 
bacterial meningitis for more than a century, though rates have declined in recent years (5-8). N. 
meningitidis, the bacterial pathogen primarily responsible for causing meningitis in this area, is 
transmitted person-to-person by close contact with the respiratory droplets or saliva of an infected 
person. The bacteria typically live in the pharyngeal passages of healthy humans without causing 
symptoms. However, following a 3-7 day incubation period, carriage with N. meningitidis can lead to 
invasive disease in some individuals, with high case fatality. Asymptomatic carriers are relatively 
common compared to cases of invasive meningococcal disease and are the primary source of 
transmission (9, 10). 
A review of meningococcal carriage in the African meningitis belt found that pharyngeal carriage ranged 
from 3% to 30% across several heterogeneous studies, that carriage is higher among contacts of cases 
than in the general population, and that carriage dynamics vary due to multiple context-specific factors, 
many of which are not fully understood (11). Despite knowledge of the key role carriers play in 
transmission, relatively little is known about the natural history of carriers, including the rate of 
acquisition and clearance of carriage, and the key factors that lead from carriage to invasive disease. 
These questions are especially important in epidemiologic contexts where the incidence of invasive 
disease is high. A greater understanding of meningococcal carriage could provide insight into the 
epidemiology of meningococcal disease including the significant geographic and temporal variation 
observed in Africa and elsewhere (1). Investigating carriage could also help inform targeted strategies 
for reducing transmission, a top priority for meningococcal research (12, 13).  
Assessing changes in carriage requires longitudinal studies that monitor carriage status among the same 
individuals over time, yet most carriage studies in Africa have been cross-sectional. Repeated cross-
sectional studies have provided significant insight, indicating that carriage varies little between seasons 
(14) and that serogroup A carriage prevalence has declined even further following the introduction of 
the conjugate meningococcal serogroup A vaccine, MenAfriVac (15-17). Longitudinal studies among the 
same individuals, however, are more challenging because of the need for long-term follow-up, the 
burden of repeated swabbing of the pharyngeal passages to determine carrier status, and the low 
sensitivity of standard culture methods in detecting meningococcal carriage (18). Very few longitudinal 
studies of N. meningitidis carriage in Africa had been undertaken prior to this study. A study in Nigeria in 
the 1970s found that children were often the first identified carrier within a household and that the half-
life of carriage was approximately three months (19). In a more recent study in Burkina Faso, the 
estimated average duration of carriage was shorter at 30 days (20). Additional empirical evidence could 
increase our understanding of transmission dynamics, inform the design of optimal vaccination 
programs to most effectively reduce transmission, and aid in planning strategies for preventing future 
outbreaks.  
In 2010, prior to the launch of the MenAfriVac mass-vaccination campaigns across the African meningitis 
belt, the African Meningococcal Carriage Consortium (MenAfriCar) had a unique opportunity to 
investigate the natural history of carriage among the general population (21, 22). To take advantage of 
this opportunity, we conducted a longitudinal pilot study of carriage among residents of Bamako, Mali. 
Our pilot study was designed as a prelude to a larger and more complex longitudinal carriage study 
MenAfriCar conduced across seven countries of the meningitis belt (23).  
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In this pilot study, we aimed to 1) standardize and test the implementation of clinical and laboratory 
protocols and 2) assess carriage status at multiple time points over an 18-month period. Our key 
considerations were to investigate how high retention in a longitudinal carriage study following entire 
households over more than a year would be and whether lab and field protocols would need to be 
revised to ensure high-quality data collection. Households were recruited for this study because of the 
close contact within families in this setting, suggesting that households are a relevant transmission unit. 
We aimed to estimate the rate of acquisition and clearance of carriage, the average duration of carriage, 
and to investigate whether carriage dynamics differed by sex and age. 
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MATERIALS AND METHODS 
Study Design  
Community engagement meetings were held in Bamako, led by the Center for Vaccine Development-
Mali, including community leaders and representatives prior to the start of all MenAfriCar carriage 
studies to provide information and gain community support for these research activities.   
Cross-Sectional Screening Study 
At the outset of our study, we conducted a cross-sectional, population-based, screening survey in the 
urban setting of the Djikoroni-para quartier in Bamako, Mali, in May 2010. We randomly selected 
households with at least two members from the existing demographic surveillance system (DSS) 
database developed and maintained by the Center for Vaccine Development-Mali. Within each 
household, we randomly selected up to five participants, one from each age group (<1 year, 1-4 years, 5-
14 years, 15-29 years, and ≥30 years). We continued recruitment until 400 participants had been 
enrolled: 20 from the youngest age group; 80 from the second youngest group; and 100 from each of 
the remaining groups. Potential participants were eligible unless they had a serious acute or long-term 
illness.  
Longitudinal Household Follow-up Study  
Beginning in July 2010 one month after the cross-sectional study ended, we selected 20 households 
from the cross-sectional study and enrolled all household members (regardless of whether the 
individual has previously participated) into a follow-up study to identify changes in carrier status over 
the next 18 months. All household members from selected households were visited every four weeks 
through November 2010 (six visits) by study teams. In December 2010, the MenAfriVac mass-
vaccination campaign took place in Bamako; all residents aged 1-29 years were eligible for vaccination. 
When additional funding became available, household follow-up resumed 10 months later in September 
2011 with visits conducted every four weeks through November 2011 (three visits).  
Sample and Data Collection 
According to a standard protocol, at the cross-sectional study visit and the nine longitudinal study visits, 
study physicians collected a single pharyngeal swab using a sterile, dacron-tipped, plastic shaft swab by 
swabbing both the posterior pharynx behind the uvula and one tonsillar fossa. Pharyngeal swabs were 
plated immediately in the field on Thayer-Martin (TM) selective agar plates and returned to the 
laboratory within six hours. At each visit, participants (or their parents if they were under 15 years of 
age) were asked to provide responses to a survey, administered orally by trained field teams and 
designed to capture information including demographics and potential risk factors. At the initial cross-
sectional visit, the head of the household or another adult also completed a questionnaire to report 
household characteristics including household size. 
Ethical Considerations 
A community consent meeting was held prior to study launch, as noted above. The head of each 
household was asked to verbally confirm his or her agreement for the individual household members to 
be invited to participate. Individual participants aged 18 years and older and parents or guardians for 
younger children were asked to provide written consent after listening to the consent form read in 
Bambara, the local language. Those aged 12 to 17 years were asked to provide written assent and 
children less than 12 years old provided oral assent. The Ethics Committees of the University of Bamako 
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Faculty of Medicine and the London School of Hygiene and Tropical Medicine and the Institutional 
Review Board (IRB) of the Fred Hutchinson Cancer Research Center approved the data collection and 
analysis. The University of Minnesota IRB also approved the data analysis.  
Laboratory Analysis 
The TM plates were incubated in 5% CO2 at 35-37C for up to 72 hours at the Center for Vaccine 
Development-Mali lab. A single colony of typical morphology was selected, sub-cultured on a blood agar 
plate (BAP), and incubated for 18-24 hours in 5% CO2 at 35-37C prior to gram staining and oxidase 
testing. The colonies remaining on the TM selective agar plate were collected with a sterile plastic loop, 
suspended in a cryotube containing 1 mL of Brain Heart Infusion (BHI) broth supplemented with 15% 
glycerol and stored at -80C as a back-up in case there was a need to go back to the original samples 
from study subjects.  
Immediately following collection, identification of carrier isolates was undertaken on site using routine 
microbiological culture methods. After all sample collection was completed, confirmatory analyses 
indicated that some samples had been misclassified. Thus, all samples stored in the BHI broth from both 
the cross-sectional and longitudinal visits were re-analyzed at the Meningococcal Reference Unit at 
Public Health England (PHE) to determine N. meningitidis carrier status. At PHE, the frozen samples were 
thawed, sub-cultured onto selective gonococcal media (Oxoid, GCVCAT), and incubated at 37C in 5% 
CO2 for 18-24 and 48-hour review. Suspected N. meningitidis colonies were tested with oxidase reagents 
and Gram film. Any oxidase-positive, Gram-negative diplococci colonies were sub-cultured for 
serological identification, which was undertaken by initial screening by the dot-blot enzyme-linked 
immunosorbent assay (ELISA) (with National Institute for Biological Standards and Control monoclonal 
antibodies (NIBSC mAbs)) for serogroups A, B, C, Y, and W and/or additional and subsequent use of in-
house polyclonal antibodies utilizing co-agglutination for serogroups B, C, Y, W, X, E, Z  (24). 
An individual was defined as a positive carrier at a given visit if N. meningitidis was isolated by PHE from 
the swab collected at that visit. All results reported here were based on laboratory results analyzed at 
PHE using the microbiological and serological methods described above.  
Data Analysis 
Data were merged, cleaned and managed using STATA version 10 (StataCorp LP 2009) and analyzed 
using R version 3.3.0 (25). Carriage prevalence was summarized by visit at the individual and household 
level. Individual time to acquisition and duration of carriage were estimated from a continuous time 
hidden Markov model (HMM) in R using the msm package (26). Due to our interest in assessing the 
natural history pre-MenAfriVac introduction and due to the 10-month gap between the follow up visits 
conducted in 2010 and 2011 during which carriage status was unknown, our primary analysis consisted 
of fitting the HMM to data from the May 2010 screening and first six monthly follow-up visits through 
November 2010. Time was defined as number of days from May 26, 2010, the first day of data collection 
during the cross-sectional screening survey. The HMM requires that initial values be supplied for certain 
parameters that are estimated during the fitting process: sensitivity and specificity were set to 0.8 and 
0.9999 respectively; the initial probability of being a carrier was set equal to the sensitivity for carriers 
and to (1-specificity) for non-carriers; and the initial values in the transition matrix were estimated by 
the msm package. The initial values did not substantially affect the final estimates. We also assessed the 
acquisition rate per month and whether the duration of carriage (equivalently, the hazard ratios for 
acquisition and clearance) differed by sex and age group (< 15 vs. ≥ 15 years old) by fitting HMMs 
including these covariates. 
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RESULTS 
During the May 2010 cross-sectional study, 400 participants from 116 households were enrolled and 
assessed for carrier status. Participants ranged from 1 month to 83 years old and households ranged 
from 3 to 60 residents. In total, 5% if individuals (20/400) from 18 (15.5%) households were identified as 
N. meningitidis carriers.  
During the launch of the longitudinal follow-up study in July 2010, all 202 residents of a subset of 20 of 
the households that participated in the cross-sectional study were invited and enrolled. Based on PHE’s 
analysis of the swabs, six of these households had at least one confirmed carrier identified during the 
previous cross-sectional study visit. Follow-up consisted of six monthly visits conducted in 2010 and 
three monthly visits conducted in 2011, resulting in 1,422 swabs analyzed to determine carrier status 
during 9 visits conducted over 18 months. Table 1 describes characteristics of all participants in the 
cross-sectional study and of all participants enrolled in longitudinal follow-up. Table 2 summarizes 
participation, by visit. The proportion of participants attending each visit out of the total number of 
participants enrolled ranged from 100% (at the first follow-up visit) to 57.4% (at the eighth follow-up 
visit). 
Among the 202 participants that attended at least one of the first six follow-up visits in 2010, 55 carriage 
events were identified from the 1,063 swabs analyzed (5.2% of swabs positive). During this time, 13% of 
individuals (27/202) were positive for carriage at least once. Most of the positive carriers, 59% (16/27), 
were observed to carry at more than one visit. Among the 150 participants who continued to attend at 
least one of the three 2011 follow-up visits, 18 carriage events were identified from the 354 swabs 
analyzed (5.1% of swabs positive). During this time, 7.3% of individuals (11/150) were positive for 
carriage at least once. During all of the follow-up visits, carriage prevalence ranged from a high of 8.5% 
of participants during the first follow-up visit to a low of 2.3% during the seventh visit (Figure 1). The 
percentage of households with at least one carrier ranged from a high of 55% during the first follow-up 
visit to a low of 16.7% during the seventh visit. The longest duration of carriage observed-i.e., the time 
period spanned by the longest string of consecutive monthly visits where an individual was identified as 
a carrier, including the screening visit, was 4.8 months. Changes in carriage status over time for all 
follow-up visits are shown in Figure 2.  
Based on the hidden Markov model fitted to the data from all swabs analyzed from the 202 individuals 
followed during the cross-sectional study plus the 6 follow-up visits in 2010, the acquisition rate per 
month was estimated to be 2.3 per 100 (95% CI: 1.3, 3.8). The mean duration of carriage was estimated 
to be 2.9 months (95% CI: 1.6, 5.4). For an individual carrier, the probability of clearing carriage within 
30 days was 0.282 (95% CI: 0.169, 0.450). The model-based estimate of the sensitivity of the assay was 
0.64 (95% CI: 0.49, 0.78) and the estimated specificity was very close to 1. The results of the hidden 
Markov model fitted to data collected during all study visits in 2010 and 2011 is given in Table S1. 
Acquisition and clearance rates were not significantly different between the first six follow-up visits and 
the three additional 2011 study visits. 
Table 3 presents the times and hazard ratios for carriage acquisition and clearance, by sex and age 
group. Males were estimated to have acquired carriage at approximately twice the rate of females (HR = 
2.21 [95% CI: 0.66, 7.38]) and cleared carriage about 66% more quickly (HR = 1.66 [95% CI: 0.51, 5.43]), 
but these differences are not statistically significant. A similar pattern was observed for individuals 
under age 15, who were estimated both to acquire and to clear carriage at approximately twice the rate 
of individuals aged 15 years and above, but these differences are also not statistically significant. 
From all swabs collected during the screening and all follow-up visits across the 18 months, we 
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identified six serogroup W carrier isolates and nine serogroup Y carrier isolates. The majority of isolates 
were classified as non-groupable (78/93; 83.9% of isolates). Serogroup W was carried by four 
individuals, (one individual at the cross-sectional screening visit only, one individual during visit eight 
only, and two individuals who both carried during visits eight and nine). None were in the same 
household. Serogroup Y was carried by three individuals (one individual during the screening visit only, 
one individual during the screening visit and visits two, four, and five, and one individual during visits 
one, two, five, and nine). None were in the same household. No A, C, or X carriers were identified.  
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DISCUSSION  
Our evidence suggests that the average duration of meningococcal carriage due to any serogroup in an 
urban setting in Mali, a hyperendemic country in the African meningitis belt, was 2.9 months, and that 
the estimated rate of acquisition of carriage was 2.3% per month. The vast majority of carrier isolates 
identified were non-groupable. Males and children may acquire and clear carriage more frequently than 
females and adults, respectively. Our study was conducted as an African Meningococcal Carriage 
(MenAfriCar) Consortium pilot study to inform a larger, multi-country study of transmission of 
meningococcal carriage within households. Our results are consistent with the estimated mean duration 
of carriage of 3.4 months (95% CI 2.7–4.4) reported in the main study (23); both estimates are lower 
than the duration of carriage usually observed in European settings (27-29). The rate of acquisition we 
report is also similar to the estimated overall rate of acquisition of meningococci of 2.4% (95% CI 1.6–
4.0) per month estimated in the main study (23). 
Our pilot study and the main multi-country MenAfriCar study differed substantially in the number of 
times each individual’s carrier status was assessed, the time between the repeated assessment of 
carriage among the same individuals, and the overall length of time during which carriage was assessed. 
In our study, we assessed carriage monthly for 6 months then, following a 10-month gap, monthly for 
three months, identifying carriers over an 18-month period. In the main MenAfriCar study, carriage was 
assessed twice a month for two months and then monthly for four months, identifying carriers over a 6-
month period. Yet, it is reassuring that results are remarkably consistent across the two studies.  
Our analysis is limited in that we cannot be certain that individuals who were found to carry N. 
meningitidis across two or more consecutive visits were colonized by the same isolates. Many N. 
meningitidis isolates were non-groupable by serological methods, thus preventing us from assessing any 
differences by serogroup. Several previous studies have also identified a high proportion of non-
groupable carriage isolates in samples collected in the African Meningitis Belt (30, 31), while others have 
not observed this trend (15, 17). While it is not clear why the proportion of unencapsulated 
meningococci is higher in this region than in other regions, one analysis suggested that air humidity may 
be correlated with acquisition of non-groupable carrier strains (30). Previous studies have estimated 
that a lower proportion of carrier isolates are non-groupable in non-hyperendemic regions such as 
Europe (32). Additional data and analyses are needed to evaluate possible causes for the predominance 
of non-groupable meningococci in a given geographic and temporal context. Understanding the 
descriptive epidemiology of non-groupable meningococci is a useful step towards generating 
hypotheses and examining possible drivers. In this regard, our data provide evidence for understanding 
carriage dynamics in the African meningitis belt, which is complementary to the findings of the larger 
MenAfriCar carriage study (23). In addition, we did not account for clustering by household in our model 
given the limited number of events observed. Both the results of the pilot study we report here and the 
results of the main study highlight the richness of data that can be obtained through longitudinal 
studies, compared to cross-sectional studies alone.  
Understanding the natural history of meningococcal carriage could have important implications for the 
prevention and control of meningococcal disease, especially in highly endemic areas. Our results and 
experience led to several lessons learned, including that confirming identification of carriers rapidly 
enough to enroll the entire household in follow-up can be challenging and that either additional efforts 
should be undertaken to prevent drop-out after a long period of study inactivity or that study duration 
should be kept as short as possible. These were central to informing the design and ensuring the success 
of longitudinal carriage studies subsequently undertaken in seven sites across the African meningitis belt 
by the MenAfriCar Consortium using a modified design compared to the one described here. Our study 
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was designed as a pilot study to demonstrate the feasibility of enrolling entire households in 
longitudinal follow-up to assess carrier status, a study design that has rarely been implemented. We 
found high participation rates across many months of follow-up and were able to identify and address 
key problems with the initial assessment of N. meningitidis carrier status. Pilot studies of complex 
clinical epidemiological designs are especially important in low-resource settings where considerable 
efforts may need to be undertaken to develop and refine protocols, test data collection and sample 
collection tools, and train staff prior to implementing larger, fully-powered studies.  
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Figure 1: Carriage prevalence among individuals during each study visit. Individual N. meningitidis 
carriage prevalence observed during each study visit. Dashed vertical bars are 95% exact binomial 
confidence intervals calculated under the assumption that carriage is independent across individuals. 
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Figure 2: Changes in individual carriage status observed at each follow-up visit. The dashed horizontal 
lines separate the households. The gray dots represent the individuals within those households. Enlarged 
red points represent meningococcal carriers detected at that visit. Individuals maintain the same vertical 
position within their household from visit to visit, so persistence of carriage can be observed by following 
a single individual horizontally over time.  
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 Table 1: A comparison of the characteristics of individuals and households that participated in the 
screening visit (May 2010) and the subsequent follow-up visits (beginning July 2010). 
Individual 
Cross-Sectional 
Screening Visit 
(n = 400) 
First Longitudinal  
Follow-up Visit 
(n = 202) 
 
Mean (SD) or N (%) Mean (SD) or N (%) 
Age 19.30 (17.56) 22.01 (16.27) 
Sex (female) 233 (58) 106 (52) 
Sore throat in past week 17 (4) 5 (2) 
Cough in past week 92 (23) 31 (15) 
Runny nose in past week 133 (33) 57 (28) 
   
Household 
Screening visit 
(n = 116) 
First follow-up visit 
 (n = 20) 
   
 Mean (SD) or N (%) Mean (SD) or N (%) 
Total residents 12.55 (10.09) 13.84 (5.78) 
Number of bedrooms 3.98 (1.42) 3.52 (1.68) 
With at least one smoker 51 (44) 7 (35) 
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Table 2: Proportion of participants attending each visit and proportion when carrier status was assessed 
for each of the longitudinal follow-up visits. 
 
Participants Attending 
Each Visit 
Carrier Status 
Assessed 
 N 
% of initial 
participants 
N 
% of visit 
participants 
Visit 1: Jul 2010 202 100 201 99.5 
Visit 2: Jul/Aug 2010 181 89.6 180 99.4 
Visit 3: Aug 2010 179 88.6 177 98.9 
Visit 4: Sep/Oct 2010 172 85.1 171 99.4 
Visit 5: Oct 2010 166 82.2 165 99.4 
Visit 6: Nov 2010 171 84.7 171 100 
     Dec 2010/Jan 2011 ------------- MenAfriVac Campaign ------------- 
Visit 7: Sep 2011 126 62.4 126 100 
Visit 8: Oct 2011 116 57.4 113 97.4 
Visit 9: Oct/Nov 2011 118 58.4 118 100 
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Table 3: A comparison of the time to acquisition and time to clearance of carriage by age and sex (along 
with 95% CIs), based on hidden Markov model results fitted to all data collected from the 202 
participants from the 20 households followed during the cross-sectional survey plus the 6 follow-up visits 
in 2010 prior to MenAfriVac introduction. 
 
Hazard ratio for acquisition 
(95% CI) 
Hazard ratio for clearance 
(95% CI) 
Sex (Males vs. Females) 2.21 (0.66, 7.38) 1.66 (0.51, 5.43) 
Age (≥ 15 vs. < 15 years) 0.41 (0.13, 1.32) 0.42 (0.13, 1.36) 
 
  
 
Time to acquisition in months 
(95% CI) 
Time to clearance in months 
(95% CI) 
Overall 36.0 (20.6, 63.0) 2.9 (1.6, 5.4) 
Males < 15 years 16.1 (6.4, 40.1) 1.6 (0.7, 3.5) 
Males ≥ 15 years 39.1 (14.3, 106.9) 3.9 (1.3, 11.5) 
Females < 15 years 35.5 (11.4, 110.2) 2.7 (0.9, 8.0) 
Females ≥ 15 years 86.3 (27.5, 270.5) 6.4 (1.7, 23.4) 
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Supplementary Appendix (S1): Results of the HMM model fit to data collected during all visits 
Based on the hidden Markov model fitted to data from all swabs analyzed from the 202 participants 
followed during the cross-sectional study visit plus both the six 2010 pre-MenAfriVac follow-up visits 
and the three 2011 post-MenAfriVac follow-up visits, the acquisition rate per month was estimated to 
1.9% (95% CI: 1.1, 3.1). The mean duration of carriage was estimated to be 4.3 months (95% CI: 2.4, 7.5). 
For an individual carrier, the probability of clearing carriage within 30 days was 0.204 (95% CI: 0.122, 
0.324). The model-based estimate of the sensitivity of the assay was 0.59 (95% CI: 0.45, 0.72) and the 
estimated specificity was very close to 1. 
Table S1 presents the time and hazard ratio for carriage acquisition and clearance, by sex and age group. 
Males were estimated to have acquired carriage at approximately 1.4 times the rate of females (HR = 
1.44 [95% CI: 0.47, 4.43]) and cleared carriage about 35% more quickly (HR = 1.35 [95% CI: 0.44, 4.08]), 
but these differences are not statistically significant. Individuals under age 15 were estimated to acquire 
infection approximately 5 times faster (95% CI: 1.7, 17.0) and clear infection at approximately 3 times 
the rate of individuals aged 15 years and above (95% CI: 1.0, 9.1). 
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Table S1: A comparison of the time to acquisition and time to clearance of carriage by age and sex 
(along with the 95% CIs), based on hidden Markov model results fitted to all data collected from the 202 
participants from the 20 households followed during the cross-sectional study visit plus both the six 2010 
pre-MenAfriVac follow-up visits and the three 2011 post-MenAfriVac follow-up visits. 
 
Hazard ratio for acquisition 
(95% CI) 
Hazard ratio for clearance 
(95% CI) 
Sex (Male vs. Female) 1.44 (0.47, 4.43) 1.35 (0.44, 4.08) 
Age (≥ 15 vs. < 15 years) 0.19 (0.06, 0.60) 0.34 (0.11, 1.04) 
   
 
Time to acquisition in months 
(95% CI) 
Time to clearance in months 
(95% CI) 
Overall 45.3 (27.3, 75.3) 4.3 (2.4, 7.5) 
Males < 15 years 21.7 (9.2, 51.2) 2.7 (1.2, 6.0) 
Males ≥ 15 years 115.1 (38.0, 348.9) 8.0 (2.9, 22.0) 
Females < 15 years 31.3 (11.7, 83.3) 3.6 (1.3, 10.1) 
Females ≥ 15 years 165.7 (56.4, 486.8) 10.7 (3.6, 31.8) 
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